NXTC stock sentiment todayNextCure Inc
Sentiment verdict
Gossip first, financials second — NEUTRAL at 65% confidence.
Last updated · cached analysis, refreshes periodically
NXTC
NextCure IncA high-risk clinical-stage biotech with a solid cash runway but a history of pipeline setbacks that demand cautious optimism.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for NXTC. Not financial advice.
Price · last 12 months
Gossip
Market chatter is currently quiet following the pivot away from their lead candidate NC318 years ago. Current focus is on NC410 (LAIR-2 fusion protein) and NC525, with investors waiting for definitive Phase 1b/2 data to prove the 'functional antibody' platform can translate to clinical efficacy.
- ·Anticipation of combination data with Pembrolizumab
- ·Low institutional volume suggesting a 'wait-and-see' approach
- ·Speculation on potential M&A if early-stage data de-risks the platform
Financial
NextCure maintains a surprisingly clean balance sheet for a micro-cap biotech, with cash reserves expected to fund operations into 2026. However, as a pre-revenue company, they are burning roughly $15-20M per quarter with no immediate path to commercialization.
- ·Cash and Equivalents: ~$100M (estimated)
- ·Zero long-term debt
- ·Negative EPS: -$1.50 to -$2.00 range annually
- ·Market Cap trading near or below cash value
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·Insiders bought a net $1.6M on the open market in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·High clinical failure rate in immunotherapy
- ·Heavy reliance on NC410 success after previous pipeline pruning
- ·Potential for future dilutive equity raises if data is delayed
Peer temperature
How direct competitors stack up against NXTC right now.
- HOTXNCRXencor, Inc.
HOTTER — superior platform validation with multiple big-pharma partnerships and a much deeper clinical pipeline.
See full analysis → - HOTALPNAlpine Immune Sciences
HOTTER — recently acquired by Vertex for $4.9B, highlighting massive premium potential for successful protein engineering platforms.
See full analysis → - COLDGLREGritstone Bio
COLDER — facing more acute liquidity concerns and higher volatility in their neoantigen program compared to NXTC's cash position.
See full analysis →
- NXTC+25.9%
- XNCR+19.5%
- ALPN—
- GLRE+1.1%
AI-generated analysis for informational purposes only. Not financial advice.